查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179875

2023 年至 2030 年干燥綜合徵的全球市場

Global Sjogren's Syndrome Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期內（2023 年至 2030 年），乾燥綜合徵的市場規模預計將以 4.2% 的複合年增長率增長。

眼睛乾澀和口乾是乾燥綜合徵 (SS) 的典型症狀，這是一種免疫系統疾病。 這種綜合徵通常與其他免疫系統疾病並存，例如狼瘡和類風濕性關節炎。 在乾燥綜合徵中，口腔和眼睛的粘膜以及分泌水的腺體首先受到影響，導致唾液和淚液分泌減少。 這種疾病在女性中更為常見。 治療的目標是緩解症狀。

市場動態

推動干燥綜合徵全球市場發展的主要因素是乾燥綜合徵和其他自身免疫性疾病的患病率增加、意識的提高、對尖端治療的需求以及強大的藥物管道。這些都有助於擴大市場。

乾燥綜合徵和其他自身免疫性疾病正變得越來越普遍，預計將推動市場增長。

乾燥綜合徵 (SS) 的主要症狀是口乾和眼乾。 該病可發生於任何年齡，但常在中年開始逐漸惡化。 乾燥綜合徵是當免疫系統攻擊人體自身組織和器官時發生的自身免疫性疾病之一。 在乾燥綜合徵中，免疫系統主要針對唾液腺和淚腺，限制它們產生眼淚和唾液的能力。 據估計，乾燥綜合徵的發病率幾乎是類風濕性關節炎 (RA) 的一半，影響 0.5% 至 1.0% 的人口。

國家生物技術信息中心 2022。 據估計，乾燥綜合徵影響了 400,000 至 310 萬成年人。 該病可發生於任何年齡，但平均發病年齡在45至55歲之間。 大約一半的患者還發現結締組織疾病，例如類風濕性關節炎和狼瘡。

Sjogren 在全世界的成人和兒童中很少見，發病率似乎沒有任何種族或地域偏見。 然而，該病明顯多見於女性，女性與男性的比例約為 9:1，與 SLE 相似。 本病好發於中年，也可發生於幼兒和老年人。

缺乏關於乾燥綜合徵藥物可用性的知識預計會阻礙市場增長。

然而，高昂的治療費用和乾燥綜合徵的影響（如急性脫水、快速體重減輕和炎症）將限制市場擴張。 在上述預測期內，由於缺乏對該疾病、其預防措施和藥物副作用的了解，乾燥綜合症市場將面臨挑戰。

COVID-19 影響分析

在 Pandis 期間，大多數行業都經歷了負面反應。 這是由於國際監管機構實施的各種預防性封鎖和其他限制措施導致其製造和供應鏈發生重大中斷。 市場也是如此。 大多數人的總體經濟狀況受到 Pandis 的嚴重影響，導致人們更傾向於從預算和消費需求中削減非必要支出。 預計這些因素將對本季度的市場產生不利影響。

人們也對提高多樣化供應鏈的彈性以確保獲得關鍵原材料產生了新的興趣。 由於迫切需要批准新的 COVID-19 疫苗和治療方法，監管機構正在簡化評估和批准程序。 這些進步有望增加未來藥物的臨床和商業成功。 然而，一旦當局解除藥物限制，全球乾燥劑行業有望復蘇。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 乾燥綜合徵等自身免疫性疾病正變得越來越普遍
      • 對尖端醫療保健的認識和需求不斷提高
    • 約束因素
      • 對乾燥綜合徵藥物的可用性了解不足
    • 商機
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章藥物類別

  • 膽鹼能激動劑
  • 標籤外藥物

第 8 章按症狀

  • 眼睛乾澀
  • 口乾舌燥

第9章按類型

  • 原發性乾燥綜合徵
  • 繼發性乾燥綜合徵

第 10 章（按銷售渠道）

  • 醫院
  • 零售店
  • 在線藥店

第11章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第12章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第13章公司簡介

  • Novartis AG
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Allergan Inc
  • Otsuka Pharmaceutical Co., Ltd
  • Santen Pharmaceutical Co., Ltd.
  • Nicox S.A
  • Argentis Pharmaceuticals, LLC
  • Auven Therapeutics
  • Abbvie Inc
  • Cellzome GmbH.
  • Biogen In.

第 14 章乾燥綜合徵-DataM 的全球市場

簡介目錄
Product Code: DMPH26

Market Overview

Sjogren's Syndrome Market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 4.2% during the forecast period (2023-2030).

The two most typical symptoms of Sjogren's syndrome (SS), an immune system illness, are dry eyes and a dry mouth. The syndrome frequently coexists with other immune system diseases like lupus and rheumatoid arthritis. The mucosal membranes and moisture-secreting glands of the mouth and eyes are typically impacted first in Sjogren's syndrome, which causes less saliva and tears to be produced. In women, the illness is far more prevalent. The goal of treatment is to diminish symptoms.

Market Dynamics

The major factors driving the global sjogren's syndrome market are that Sjogren's syndrome and other autoimmune illnesses are becoming more common, increasing awareness and the need for cutting-edge medical care, additionally, a strong drug pipeline has contributed to the market's expansion

Sjogren's syndrome and other autoimmune illnesses are becoming more common and are expected to drive the market's growth.

The primary symptoms of Sjogren syndrome (SS) are dry mouth and eyes. The illness can happen at any age, but it often starts to worsen progressively in middle adulthood. Sjogren syndrome is one of a vast set of ailments known as autoimmune disorders that take place when the immune system targets the body's own tissues and organs. In Sjogren syndrome, the immune system predominantly targets the salivary glands and the lacrimal glands, which limit the glands' capacity to secrete tears and saliva. The incidence of Sjogren syndrome is close to half that of rheumatoid arthritis (RA), or it affects 0.5% to 1.0% of the population, according to

The National Centre for Biotechnology Information 2022. Sjogren's syndrome affects between 400,000 and 3.1 million adult people. Although this illness can affect individuals of any age, the average onset of symptoms is between the ages of 45 and 55. Rheumatoid arthritis and other connective tissue illnesses, such lupus, are also present in about half of patients.

Sjogren has been recorded in adults and children less frequently throughout the world, and there doesn't seem to be any racial or geographic bias in incidence. However, the disorder has a clear preference for females, and similar to SLE, the female: male ratio is around 9:1. The condition typically manifests in middle age, but it can also affect young children and the elderly.

Lack of knowledge regarding the availability of the Sjogren's syndrome drug is expected to hamper the market's growth.

However, the high cost of treatment and sjogren's disease consequences such acute dehydration, rapid weight loss, and inflammation will restrain market expansion. During the aforementioned projection period, the sjogren's syndrome market will face challenges from a lack of knowledge regarding the condition, its preventative measures, and drug side effects.

COVID-19 Impact Analysis

During the Pandamic, most industries experienced negative repercussions. This can be attributed to significant disruptions in their manufacturing and supply chains as a result of various preventative lockdowns and other limitations imposed by international regulatory organizations. The market is the same. The general economic status of the majority of people has been severely hit by the pandamic, which has also resulted in a fall in consumer demand as people are more inclined to eliminate non-essential expenditure from their budgets. During the projected period, it is anticipated that the aforementioned factors will have a negative impact on the market.

There is also a resurgence of interest in enhancing the resilience of diversified supply chains to provide reliable access to vital raw materials. Due to the urgent need to approve new COVID-19 vaccines and therapies, regulatory agencies have simplified the evaluation and approval processes. It is hoped that these advancements will increase the clinical and commercial success of future medicines. However, it is projected that the worldwide Sjogren syndrome (SS) industry will recover once the relevant governing authorities start pharmaceuticals lift such imposed lockdowns.

Segment Analysis

The hospital's segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Hospitalization rates were greater for SS patients than for the general population. Patients with SS were more likely than comparators to be hospitalized for endocrine/metabolic illnesses, cardiovascular diseases, musculoskeletal diseases, connective tissue disorders, and traumas. People with Sjogren's disease are more likely to need inpatient hospital care for infections picked up in the community, especially those of the lungs and intestines, according to Sjogren's syndrome News from October 2022. Hospitalizations for opportunistic infections, such as mycobacterium infections and the chickenpox/shingles virus (zoster), are also more common in this patient population. Sjogren's patients had a 98% higher overall hospitalization rate for a first infection than healthy individuals did.

According to experts from the University of Montpellier in France, while the effect of infections on outcomes related to other autoimmune illnesses has been extensively discussed, little is known regarding the prevalence of severe infections necessitating hospitalization in Sjogren's patients.

Geographical Analysis

North America holds the largest market share in the global Sjogren's Syndrome market.

North America dominates the global Sjogren's syndrome market primarily due to its large population, excellent medical infrastructure, and high-income levels. Around 1 in 200 Americans are thought to be affected by Sjogren's syndrome, according to the Johns Hopkins Sjogren's Center 2021. A team of knowledgeable professionals must evaluate patients who believe they may have Sjogren's syndrome. The doctors at the Jerome Greene Sjogren's syndrome Center at Johns Hopkins have great experience in Sjogren's syndrome diagnosis, treatment, and research. Their knowledge is currently centralized in a facility easily accessible on the Johns Hopkins Bayview campus in Baltimore, Maryland. Rheumatologists, ophthalmologists, neurologists, and gynecologists make up the company team and review 200-300 new patients with a suspected or confirmed diagnosis of Sjogren's syndrome each year.

Additionally, many businesses are there, and the syndrome that propels the region is developing. For instance, in September 20222, advancement prospects increase once Novartis completes a Phase II Sjogren's syndrome trial. The team at Clinical Trials Arena also looks at a leishmaniasis trial suspension, a lymphoma trial termination, and trial completions for endometriosis and dry eye syndrome. Remibrutinib (LOU-064) from Novartis saw an increase in its Phase Transition Success Rate (PTSR) of eight points to 34% in Sjogren's syndrome following the conclusion of Phase II research.

Competitive Landscape

The sjogren's syndrome market is moderately competitive with local and global companies' presence. Novartis AG, Allergan Inc, Otsuka Pharmaceutical Co., Ltd, Santen Pharmaceutical Co., Ltd., Nicox S.A, Argentis Pharmaceuticals, LLC, Auven Therapeutics, Abbvie Inc Cellzome GmbH, Biogen Inc and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in November 2022, For those with autoimmune and chronic inflammatory disorders, including Sjogren's syndrome, Motto Health has opened a kind of virtual clinic with rheumatologists and medical specialists, the startup revealed. The technology enables patients to manage and track symptoms, schedule virtual consultations with physicians, and obtain individualized treatment regimens using an online application.

Novartis AG.

Overview: A healthcare firm called Novartis AG (Novartis) specializes in the development, production, and marketing of prescription and over-the-counter medicines, as well as products for eye care. Among other things, it offers medicines for the treatment of infections, cancer, cardiovascular disease, dermatological issues, neurological disorders, ophthalmic and respiratory illnesses, and cancer. Through Sandoz, the business provides biosimilars and generic medications. Through The Novartis Institutes for BioMedical Research, Novartis carries out research in a number of illness areas (NIBR).

Product Portfolio:

Hydroxychloroquine (Plaquenil): The anti-rheumatic medicine hydroxychloroquine (Plaquenil) is a disease-modifying medication (DMARD). It can lessen arthritic pain and swelling. It might stop joint deterioration and lessen the possibility of permanent impairment. The drug hydroxychloroquine belongs to a group of drugs that were initially used to treat and prevent malaria.

Key Development: In September 2022, Sjogren's syndrome Phase II trial by Novartis is now complete. After that, they suspend the Phase I study for visceral leishmaniasis, end the Phase I trial for B-cell lymphoma, and complete the Phase I trials for endometriosis and dry eye syndrome.

The global Sjogren's Syndrome market report would provide access to approx.: 45+ market data tables, 40+ figures, and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Sjogren's syndrome and other autoimmune illnesses are becoming more common
      • 4.1.1.2. Increasing awareness and the need for cutting-edge medical care
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of knowledge regarding the availability of the Sjogren's syndrome drug
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Cholinergic Agonists
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Off-Label Drugs

8. By Symptoms

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
    • 8.1.2. Market Attractiveness Index, By Symptoms
  • 8.2. Dry eyes
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Dry mouth

9. By Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.1.2. Market Attractiveness Index, By Type
  • 9.2. Primary Sjogren's Syndrome
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Secondary Sjogren's Syndrome

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospitals
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacy
  • 10.4. Online Pharmacy

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Symptoms
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Novartis AG
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Allergan Inc
  • 13.3. Otsuka Pharmaceutical Co., Ltd
  • 13.4. Santen Pharmaceutical Co., Ltd.
  • 13.5. Nicox S.A
  • 13.6. Argentis Pharmaceuticals, LLC
  • 13.7. Auven Therapeutics
  • 13.8. Abbvie Inc
  • 13.9. Cellzome GmbH.
  • 13.10. Biogen In.

LIST NOT EXHAUSTIVE

14. Global Sjogren's Syndrome Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Application
  • 14.3. Contact Us